MGD%NIHCU.BITNET@CUNYVM.CUNY.EDU (07/08/88)
Following are the texts of two Requests for Applications
for grant proposals dealing with the genome project.
Note that multi-disciplinary approaches are encouraged. In
addition to scientists in all areas of the biological sciences
we encourage the participation of those in disciplines that
have not previously received major amounts of support from the
NIH, such as computer science, materials science, physics,
mathematics and engineering. Additional
information can be obtained from me or Irene Eckstrand at
(301) 496-7137 or MGD@NIHCU.BITNET.
Mark Guyer
CHARACTERIZATION OF THE GENOMES OF HUMANS AND MODEL
ORGANISMS
RFA AVAILABLE: 88-GM-02
P.T. 34; K.W. 1002019, 0755045
National Institute of General Medical Sciences
Application Receipt Date: September 22, 1988
BACKGROUND INFORMATION
The National Institute of General Medical Sciences (NIGMS) supports research
in the field of genomic analysis, with the goal of developing detailed genetic
and physical maps and, eventually, determining the complete sequence of the
DNA of a number of organisms, including man. It is expected that this
knowledge will ultimately be applied to the prevention, diagnosis, and
treatment of human disorders. The objective of this Request for Applications
(RFA) is to stimulate innovative research that will rapidly improve our
ability to analyze the entire genome of an organism.
RESEARCH GOALS AND SCOPE
The NIGMS invites applications from interested investigators for research
which involves the further development of physical maps of the human genome;
development of physical maps and/or determination of the DNA sequence of the
genome of one of the following model organisms: yeast, Drosophila, mouse or
the nematode worm, Caenorhabditis elegans; or development of new approaches
for determination of such mapping or sequence information. [Research projects
directed toward these goals but which utilize other organisms are
appropriately submitted in response to an existing NIH Program Announcement
(NIH Guide for Grants and Contracts, Vol. 16, No. 18, p. 11; May 27, 1987)].
To be considered responsive to this RFA, proposals must be primarily directed
toward the development of new mapping and sequencing data or the development
of new methodological approaches which will increase the accuracy, ease, and
rapidity with which such mapping and sequence determination can be achieved.
Innovative approaches to obtaining such information are encouraged.
Utilization of physical mapping and DNA sequence data for the analysis and
Vol. 17, No. 22, July 1, 1988 - Page 6
characterization of genomic information is also encouraged as part of the
proposed projects. However, applications in which the primary goal is the
study of the biology of specific genomic regions (particularly regions related
to disease genes), and in which mapping or sequence data are to be obtained
only as a necessary first step toward that end, will not be considered
responsive to this announcement.
MECHANISM OF SUPPORT
Support will be through research grants including individual projects grants
(RO1, R29) and program projects (P01). The total amount of support for grants
under this RFA is contingent upon the appropriation of funds for this purpose.
The number of awards will be determined by the merit of the proposals, by
their relevance to the program goals, and availability of funds. It is
anticipated that in Fiscal Year 1989 up to five million dollars will be
allocated to the research initiatives described in this RFA, allowing
approximately 10-30 awards to be made. This amount may be increased if a
large number of highly meritorious applications are received and if funds are
available.
STAFF CONTACT
Applicants should request the complete RFA and obtain additional information
from:
Dr. Mark Guyer or Dr. Irene Eckstand
National Institute of General Medical Science
Westwood Building, Room 918
National Institute of Health
Bethesda, Maryland 20892
Telephone: (301) 496-7137
NEW TECHNOLOGY FOR GENOMIC ANALYSIS
RFA AVAILABLE: 88-GM-03
P.T. 34; K.W. 1002019, 0755045, 1004000, 0735000
National Institute of General Medical Sciences
Application Receipt Date: December 1, 1988
BACKGROUND INFORMATION
The National Institute of General Medical Science (NIGMS) supports research in
basic genetics, including research directed toward the construction of
detailed genetic and physical maps of the genomes of a number of organisms,
including man, and the determination of the complete sequence of the DNA of
those organisms. This knowledge will ultimately be applied in biomedical
research for the diagnosis, treatment, and prevention of human disease.
Significant advances have been made during the past decade in the techniques
available for determination of genomic structure and organization and of
nucleic acid sequences. The objective of the Request for Applications (RFA)
is to stimulate innovative research that will lead to further improvements in
the speed and efficiency of map construction and DNA sequence determination,
so that major research efforts such as determining the entire DNA sequence of
any organism will become practical in terms of both time and cost.
RESEARCH GOALS AND SCOPE
The NIGMS invites applications from investigators for research that will lead
to new or improved technology applicable to genomic analysis. The object of
this program is to make substantial improvements in the rapidity, efficiency
and accuracy with which genetic mapping, physical mapping, and DNA sequence
information can be obtained, analyzed, and distributed. Multi-disciplinary
approaches to the attainment of these goals are encouraged; in addition to
scientist in all areas of the biological sciences, we encourage the
participation of scientist in disciplines which have not previously received
major amounts of support from the National Institute of Health (NIH), such as
computer science, materials science, physics, mathematics and engineering.
MECHANISM OF SUPPORT
Support will be through research grants including individual project grants
(R01, R29) and program projects grants (P01). The total amount of support for
grants under this RFA is contingent upon the appropriation of funds for this
purpose. The number of awards will be determined by the merit of the
Vol. 17, No. 22, July 1, 1988 - Page 7
proposals and by the relevance to the program goals, as well as by
availability of funds. It is anticipated that in Fiscal Year 1989 up to five
million dollars will be allocated to the research initiatives described in
this RFA, allowing approximately 10-30 awards to be made. This amount may be
increased if a large number of highly meritorious applications are received
and if funds are available.
STAFF CONTACT
Applicants should request the complete RFA and obtain additional information
from:
Dr. Mark Guyer or Dr. Irene Eckstrand
National Institute of General Medical Sciences
Westwood Building, Room 918
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-7137
FULL TEXT OF RFAs FOR ONLINE ACCESS
CHARACTERIZATION OF THE GENOMES OF HUMAN AND MODEL ORGANISMS
RFA AVAILABLE; 88-GM-02
P.T. 34; K.W. 1002019, 0755045
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
APPLICATION RECEIPT DATE: SEPTEMBER 22
The National Institute of General Medical
Sciences (NIGMS) invites applications for
grants to support research projects directed
toward characterization of the human genome or
the genomes of certain model organisms. The
objective is to stimulate innovative research
that will rapidly improve our ability to
analyze the entire genome of an organism, with
the goal of applying this knowledge to the
analysis of the human genome and, ultimately,
to the prevention, diagnosis, and treatment of
human disorders. Special funds will be
available to support competitive research
programs that further these goals. Potential
applicants are strongly advised to contact
NIGMS staff before submitting applications for
support.
BACKGROUND
The analytical methods available to
contemporary molecular geneticists have
advanced to the point that it is feasible to
consider development of highly detailed genetic
and physical maps of the human genome and,
eventually, the determination of the complete
sequence of human DNA. A number of advisory
committees have recommended that the National
Institutes of Health (NIH) and other government
agencies institute research programs with the
goal of obtaining such information. In
response to those and other recommendations,
the NIH has committed itself to the development
of improved research capabilities in genomic
analysis, including both conceptual and
technological aspects of genetic mapping,
biochemical analysis of DNA (including physical
mapping), DNA sequence determination,
information management and materials handling.
In addition to the resources which NIH had
previously committed to support research in
this field, the United States Congress
appropriated $17.2 million to the NIH in Fiscal
Year (FY) 1988 (as well as additional funds to
other agencies), specifically for support of
research on genomic analysis.
In May 1987, the NIH issued two program
announcements, entitled "New Approaches to the
Analysis of Complex Genomes" and
"Computer-based Representation and Analysis of
Molecular Biology Data," (NIH Guide for Grants
and Contracts; vol. 16, no. 18 - May 29, 1987 -
pp. 9, 11). These solicitations described a
number of research topics related to genomic
analysis. Such topics included development of
methodology and technology and the analysis of
both prokaryotic and eukaryotic genomes. The
two announcements are referred to here to
emphasize that all other institutes at NIH, as
well as NIGMS, continue to encourage and
support research on the topics described in
those broad announcements.
In October 1987, the NIGMS published a Request
for Applications (RFA) for research initiatives
in the area of genomic analysis that were of
special interest to the NIGMS. Targeted funds
will also be available in FY 1989, thus
prompting this new RFA, which is similar to the
earlier one and focuses on specific research
initiatives.
The development of the genetic map of the human is being actively pursued. A
map in which polymorphic markers are spaced, on the average, every ten
centiMorgans (cM) is available, and work is proceeding to reduce the spacing
to an average of one to five cM. The availability of such a highly refined
human genetic map will greatly facilitate the creation of physical maps,
isolation of human genes, development of tools for the diagnosis of genetic
disorders, research into the organization of the human genome and, ultimately,
determination of the DNA sequence of the human. The construction of high
resolution physical maps of human DNA comprises the next set of goals for the
project of analyzing the human genome. These maps include both restriction
maps based on the location of recognition sites for infrequently cutting
restriction enzymes and a complete set of ordered, overlapping clones of human
DNA.
Studies of model organisms have been instrumental in the achievement of many of
the technical and conceptual advances which have brought the analysis of large,
complex genomes within our capabilities. Studies, using a variety of model
organisms, are underway with support from several sources. It is NIGMS' belief
that the genetic maps, physical maps, and the genomic DNA sequences of four
groups of model organisms--yeast, Drosophila, mouse and nematode worms--will be
particularly valuable research tools for understanding the organization of all
eukaryotic genomes, including that of the human. In addition, the further
improvements in methodology generated by such research will have many important
applications.
It is important to emphasize that valuable research in this field is by no
means limited to these four groups of organisms. Investigators are reminded
that research on other organisms is encouraged under the broad NIH Program
Announcements that were described above.
RESEARCH GOALS
The primary goal of the research program described in this RFA is the
acquisition of physical mapping and sequence data focused on the topics
described below. To be considered responsive to this RFA, proposals must be
primarily directed toward the development of new mapping and sequencing data or
the development of new methodological approaches to obtaining such
information. Creative, innovative approaches are particularly encouraged.
Utilization of physical maps and DNA sequences for the analysis and
characterization of genomic information is encouraged as part of all of these
proposed mapping and sequencing projects. However, proposals in which the
primary goal is the study of the biology of specific genomic regions
(particularly regions related to disease genes), and in which mapping or
sequence data are to be obtained only as a necessary first step toward that
end, will not be considered responsive to this Announcement.
Physical Maps of the Human
Physical maps of human DNA are in the early stages of development. Major
technological advances are still required to produce such maps efficiently and
rapidly and to increase the resolution and the accuracy of such maps.
Applications should focus on one or more of the following: (a) isolation of a
set of ordered, overlapping clones comprising a chromosome or a chromosomal
region, (b) development of a restriction map of a chromosomal segment or an
entire chromosome, (c) improvement of techniques for developing these maps.
Mapping and Sequencing of the Genomes of Model Organisms
Research projects that will lead to the characterization of the genomes of a
number of model organisms are under way. Construction of the genetic and
physical maps and determination of the sequences of the DNA of four of these
organisms, Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila
melanogaster, and Mus musculus (as well as of closely related organisms), will
be particularly useful. Applications in response to this aspect of the RFA
should focus on the following objectives:
Expansion of the genetic map, refinement and closure of physical maps, and
linkage of the genetic and physical maps of the four organisms listed above;
Determination of the DNA sequence of chromosomal segments, complete
chromosomes, or the entire genomes of these four organisms;
Improvement of the genetic or physical maps or determination of DNA
sequence of organisms closely related to the four organisms listed above
(e.g., Schizosaccharomyces pombe) when such information would serve to
advance the analysis of the genome of one of the four organisms of primary
interest.
Research to be supported under this part of the RFA is focused on these four
model organisms because it is expected that progress can be made rapidly and
will be of considerable benefit to other basic science projects, as well as to
the program for characterizing the human genome. Again, investigators are
reminded that research with these objectives that utilizes other organisms is
encouraged under the broad NIH Program Announcements.
As the goals of this RFA represent large and complex initiatives, it is
expected that a number of laboratories will be involved in the construction of
each map or extended DNA sequence. Progress will be accelerated by cooperation
and interaction among investigators, and awardees will be expected to share
information and to work closely with other laboratories involved in related
projects. It is expected that all materials and information derived from this
work will be made available to the scientific community and to the relevant
repositories and data collections in a timely manner. It is also possible that
periodic meetings of awardees will be encouraged.
MECHANISM OF SUPPORT
Support for this program will be through research grants, including individual
project grants (R01, R29) and program project grants (P01). Applications
submitted by collaborating investigators from more than one institution are
encouraged and can be supported by consortium arrangements. Policies that
govern research grant programs of the NIH apply to this program.
The total amount of support of grants under this RFA is contingent upon the
appropriation of funds for this purpose. The number of awards will be
determined by the merit of the proposals and by their relevance to program
goals, as well as by the availability of funds. It is anticipated that in FY
1989 up to five million dollars will be allocated to the research initiatives
described in this RFA, allowing approximately 10-30 awards to be made. This
amount may be increased if a large number of highly meritorious applications
are received and if funds are available.
APPLICATION AND REVIEW PROCEDURES
The following review procedure will apply to applications submitted in response
to this Request for Applications:
First, all applications will be screened for responsiveness to this RFA by
NIGMS staff. Those which are deemed non-responsive will be considered as
regular applications and will either be returned or will be sent to the
Division of Research Grants for review by the usual NIH peer review procedures.
Second, if a large number of responsive applications is received, they will
undergo a preliminary peer review to identify the most meritorious ones.
Applications which are deemed non-competitive by this peer review will receive
only a brief critique and will not be reviewed further.
Third, one or more special NIGMS peer review committees will evaluate the
remaining applications for scientific and technical merit. Following this
scientific review, the applications will be secondarily reviewed by the
National Advisory General Medical Sciences Council. Review criteria include
the following:
Overall scientific merit of the research;
Potential value of the research for furthering the goals described in this
Request for Applications (in some cases, innovative approaches will be
required to attain these goals);
Feasibility of the research and adequacy of the experimental design;
Training, experience, and research competence, of the investigator(s);
Adequacy of available facilities;
Provisions for the protection of human subjects and the humane care of
animals; and
Appropriateness of the requested budget for the work proposed.
Applications should be submitted using the new form PHS 398 (rev. 9/86). The
RFA label available in the revised application kit must be affixed to the
bottom of the face page. Failure to use this label could result in delayed
processing of the application such that it may not reach the review committee
in time. Application kits are available in the business or grants office at
most academic or research institutions, or from the Division of Research
Grants, National Institutes of Health. Applications will be accepted in
accordance with the following schedule:
TIMETABLE
Receipt Date: September 22, 1988
IRG Review: January - March, 1989
Council Review: May, 1989
Earliest Funding Date: July 1, 1989
It is essential that applicants type "CHARACTERIZATION OF THE GENOMES OF HUMANS
AND MODEL SYSTEMS" and the RFA number 88-GM-02 on line 2 on the face page of
the application form. The original and four copies of the application should
be submitted to the following office:
Grant Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
National Institutes of Health
Bethesda, Maryland 20892**
To expedite the review process, submit two copies of your application directly
to :
Office of Review Activities
National Institute of General Medical Sciences
Westwood Building, Room 949
National Institutes of Health
Bethesda, Maryland 20892
Funding decisions will be based on recommendations of the initial review groups
and the National Advisory General Medical Sciences Council regarding scientific
merit and program relevance.
It is strongly recommended that potential applicants contact NIGMS staff to
discuss research objectives. Each prospective applicant is advised to submit,
by Aug. 1, a letter of intent which includes a descriptive title of the
proposed research and names of key members of the program, including
collaborators. This letter is requested to provide NIH staff with an
indication of the number and scope of applications to be reviewed. It does not
commit the prospective applicant to submit an application nor is it a
requirement for submission of an application. For more information, applicants
may contact:
Dr. Mark Guyer or Dr. Irene Eckstrand
National Institute of General Medical Sciences
Westwood Building, Room 918
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-7137
NEW TECHNOLOGY FOR GENOMIC ANALYSIS
RFA AVAILABLE: 88-CM-03
P.T. 34; K.W. 1002019, 0755045, 1004000, 0735000
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
APPLICATION RECEIPT DATE: DECEMBER 1
The National Institute of General Medical Sciences (NIGMS) invites applications
for grants to support research projects directed toward the development of new
technology applicable to genetic mapping, physical mapping of chromosomes, and
acquisition and interpretation of DNA sequences. The objective is to stimulate
creative, innovative research that will substantially improve the rapidity,
efficiency and accuracy with which mapping and DNA sequence data can be
obtained, analyzed, and distributed. Multi-disciplinary approaches to the
attainment of these goals are encouraged; in addition to scientists in all
areas of the biological sciences, we encourage the participation of scientists
in disciplines, such as computer science, materials science, physics,
mathematics and engineering, that have not previously been major recipients of
support from the National Institutes of Health (NIH). Special funds will be
available to support competitive research efforts that further these aims.
Potential applicants are strongly advised to contact NIGMS staff before
submitting applications for support.
BACKGROUND
The National Institutes of Health (NIH) is interested in effecting rapid
advances in the field of genomic analysis. New information about genomic
organization and DNA sequences will afford opportunities for the understanding
of basic biological processes and for clinical applications. In the past
several years, major advances have been made in the methods and techniques
available to molecular biologists and geneticists for the analysis of large,
complex genomes. Examples include new electrophoretic methods, which have
extended, by one to two orders of magnitude, the useful range of separation of
large DNA molecules; improved vectors, which have allowed a similar increase
in the size of DNA fragments that can be cloned and maintained; new
restriction enzymes and new strategies for generating very high molecular
weight DNA fragments; new instruments for DNA synthesis and sequencing; and
improved methods for linkage analysis, data base management, and DNA sequence
analysis. As a result of these and other methodological improvements, it has
become possible to consider the construction of high resolution genetic and
physical maps and, ultimately, the determination of the complete sequence of
the DNA of any organism of interest, including man.
For many years, the NIH has provided substantial support for research related
to mapping and sequencing. In addition, during the past two years, the federal
government has initiated several programs to specifically stimulate further
research in genomic analysis. In Fiscal Year (FY) 1988, Congress appropriated
$17.2 million to the NIH for this purpose. It is expected that another $12
million will be available for new awards in FY 1989. In addition to this
Request for Applications (RFA), the NIH currently is soliciting research
proposals through two program announcements, "New Approaches to the Analysis of
Complex Genomes" (NIH Guide for Grants and Contracts, vol. 16, no. 18 [May 29,
1987], p. 11) and "Computer-based Representation of Molecular Biology Data"
(NIH Guide for Grants and Contracts, vol. 16, no. 18 [May 29, 1987], p. 9), and
another RFA, "Characterization of the Genomes of Humans and Model Organisms"
(this issue of the NIH Guide for Grants and Contracts).
Several advisory committees have been convened to consider the issues raised
by this new focus on genomic analysis. These committees have agreed that high
resolution maps of the human genome and the complete sequence of human DNA
would be very valuable tools for biomedical research. They also have agreed
that it is essential to obtain comparable information about the genomes of
several other organisms, both to aid the development of the new techniques
necessary to analyze the human genome and to provide parallel information that
will be needed to interpret the human data. The advisors expressed the
additional opinion that, although techniques are currently available for
expanding the human genetic map and for beginning construction of a variety of
physical maps of human chromosomes, new methods are needed to increase the
efficiency and accuracy of the mapping efforts. Furthermore, current
techniques for DNA sequence determination are not adequate to allow the human
DNA sequence to be determined within an acceptable period of time or at an
acceptable cost. Therefore, each of the committees strongly recommended that
support for improving the technological capabilities for all aspects of
genomic analysis should be given a very high priority in the initial stages of
the genome project.
RESEARCH_GOALS
This Request for Applications is intended to emphasize the intention of the
NIGMS to support research that will lead to improvements in the methodology
used for genomic analysis. Improvements are needed in the methods for, among
others, the following aspects:
o genetic linkage mapping;
o locating specific genes on the genetic map;
o generating, purifying, and cloning large DNA fragments;
o restriction mapping, especially mapping of rare restriction sites;
o producing overlapping sets (contigs) of DNA fragments derived from
specific chromosomal regions and connecting such
overlapping sets into more extensive physical maps;
o determining relationships between genetic and physical maps;
o mapping genes which are active in specific tissues or at specific
developmental stages;
o determining DNA sequence;
o storing, analyzing and distributing the data obtained in each of these
activities;
o storing the materials generated by all of these activities; and
o automating the techniques used for genomic analysis.
Research grant applications that address these, or other, areas that would
improve our ability to attain the goals of the genome project, would be
appropriate to submit in response to this RFA.
The ultimate goal of the genome project is to determine the sequence of the
three billion base pairs of human DNA. Before this can be accomplished, many
technical advances will be needed. Some of these will result from
developments that originate from work using model systems, while in other
cases the technological developments will result from projects focused on
small regions of the human genome. Similarly, some advances will be
accomplished by individual research laboratories, others by larger,
multidisciplinary groups. Research grant applications involving each type of
scientific subject and organizational structure are encouraged.
Methodological improvements have played an important role in advancing
biological research. One reason that such technology development has been so
successful is that it has been driven by the need to solve specific scientific
problems. Therefore, it is reasonable to expect that, within the larger goals
of the genome program, the most successful new technologies will come from
those research groups in which the technological improvements occur in the
context of solving specific research problems relating to genomic analysis.
As noted above, it will be necessary to significantly increase the rate at
which mapping and sequence data are acquired if the goal of the genome project
is to be attained. It has been suggested, therefore, that component projects
of the human genome effort be directed toward improving by five- to ten-fold
the scale and/or efficiency with which mapping, sequence determination, and
data analysis can be done. While this will not be a review criterion for
proposals submitted in response to this RFA (see Application and Review
Procedures), such an incremental increase can serve as a useful benchmark in
the design of a proposed research program. Achievement of such a significant
improvement in analytical capability may require rethinking the way in which
comparable technological problems have previously been addressed; entirely new
approaches may be required and are encouraged. It is recognized and
appreciated that novel approaches may involve a considerable degree of risk.
The NIGMS considers that high-risk, high pay-off projects are appropriate to
submit in response to this announcement and can contribute signficantly to the
achievement of the goals of the genome project.
As the goals of this RFA involve the development of new technologies, which
are intended to be applied broadly and to be used by many laboratories, it is
expected that all materials and information derived from this work will be
made available to the scientific community in a timely manner. Progress will
be accelerated by cooperation and interaction among investigators, and
awardees will be expected to share information and to work closely with other
laboratories involved in related projects. It is also possible that periodic
meetings of awardees will be held.
MECHANISM OF SUPPORT
Support for this program will be through research grants, including individual
project grants (R01, R29) and program project grants (P01). Applications
submitted by collaborating investigators from more than one institution are
encouraged and can be supported by consortium arrangements. Policies that
govern research grant programs of the NIH apply to this program.
The total amount of support of grants under this RFA is contingent upon the
appropriation of funds for this purpose. The number of awards will be
determined by the merit of the proposals and by their relevance to program
goals, as well as by the availability of funds. It is anticipated that in
Fiscal Year 1989, up to five million dollars will be allocated to the research
initiatives described in this RFA, allowing approximately 10-30 awards to be
made. This amount may be increased if a large number of highly meritorious
applications are received and if funds are available.
APPLICATION AND REVIEW PROCEDURES
The following review procedure will apply to applications submitted in response
to this Request for Applications:
First, all applications will be screened for responsiveness to this RFA by
NIGMS staff. Those deemed non-responsive will either be returned to the
applicant or will be considered as regular applications and sent to the
Division of Research Grants for review by the usual NIH peer review procedures.
Second, if a large number of responsive applications is received, they will
undergo a preliminary peer review to identify the most meritorious ones.
Applications which are deemed non-competitive by this peer review will receive
only a brief critique and will not be reviewed further.
Third, one or more special NIGMS peer review committees will evaluate the
remaining applications for scientific and technical merit. Following this
scientific review, the applications will be secondarily reviewed by the
National Advisory General Medical Sciences Council. Review criteria include
the following:
Overall scientific merit of the research;
Potential value of the research for furthering the goals described in this
Request for Applications;
Feasibility of the research and adequacy of the experimental design;
Training, experience, and research competence, of the investigator(s);
Adequacy of available facilities;
Provisions for the protection of human subjects and the humane care of
animals; and
Appropriateness of the requested budget for the work proposed.
Funding decisions will be based on recommendations of the initial review groups
and the National Advisory General Medical Sciences Council regarding scientific
merit and program relevance.
Applications should be submitted using the new form PHS 398 (rev. 9/86). The
RFA label available in the revised application kit must be affixed to the
bottom of the face page. Failure to use this label could result in delayed
processing of the application, such that it may not reach the review committee
in time. Application kits are available in the business or grants office at
most academic or research institutions, or from the Division of Research
Grants, National Institutes of Health. Applications will be processed in
accordance with the following schedule:
TIMETABLE
Receipt Date: December 1, 1988
IRG Review: February - March, 1989
Council Review: May, 1989
Earliest Funding Date: July 1, 1989
It is essential that applicants type "NEW TECHNOLOGY FOR GENOMIC ANALYSIS" and
the RFA number 88-GM-03 on line 2 on the face page of the application form.
The original and four copies of the application should be submitted to the
following office:
Grant Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
National Institutes of Health
Bethesda, Maryland 20892**
To expedite the review process, two copies of the application should be
submitted directly to:
Office of Review Activities
National Institute of General Medical Sciences
Westwood Building, Room 949
National Institutes of Health
Bethesda, Maryland 20892
It is strongly recommended that potential applicants contact NIGMS staff to
discuss research objectives. Each prospective applicant is advised to submit,
by October 15, a letter of intent which includes a descriptive title
and names of key members of the program, including
collaborators. This letter is requested to provide NIH staff with an
indication of the number and scope of applications to be reviewed. It does not
commit the prospective applicant to submit an application nor is it a
requirement for submission of an application. For more information, applicants
may contact:
Dr. Mark Guyer or Dr. Irene Eckstrand
National Institute of General Medical Sciences
Westwood Building, Room 918
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-7137
Network address: MGD@NIHCU.BITNET
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
5333 Westbard Avenue
Bethesda, Maryland 20816